A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
NCT05160636 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 999
Last updated 2026-03-31
Summary
The main purpose of this study is to understand:
* the symptoms of COVID-19 or influenza- health-related outcomes of people with COVID-19 or influenza (influenza only included in updated study analyses)
* the potential effects of COVID-19 vaccines in people with COVID-19
This study will enroll participants who are:
* 18 years or older
* reported to have symptoms with tests that have confirmed illness. The tests can be taken at any of CVS pharmacy COVID-19 or influenza test sites.
The study will collect vaccine history information from participants who are ready to take part in the study. Participant will be emailed a form with questions about their health related to COVID-19 or influenza during multiple follow-ups over a 6-month period.
Conditions
Interventions
- BIOLOGICAL
-
Receipt of Pfizer BioNTech COVID-19 vaccine
Sponsors & Collaborators
-
CVS Caremark
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-01-31
- Primary Completion
- 2027-01-31
- Completion
- 2027-01-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
NCT06178991 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
NCT05333289 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
NCT06680375 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
NCT05827926 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.
NCT05858450 ·Status: COMPLETED
-
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
NCT05375838 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza
NCT05052697 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine
NCT01465035 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
NCT05972174 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza
NCT05227001 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
NCT05091307 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
NCT06237049 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults
NCT00506350 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine
NCT02014168 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
NCT04956575 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
NCT05827068 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity of Influenza Vaccinations
NCT06518577 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
NCT05027932 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults
NCT05788237 ·Status: COMPLETED ·Phase: PHASE1
-
A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.
NCT05184387 ·Status: COMPLETED
-
Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults
NCT01389479 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
NCT01236040 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
NCT05606965 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults
NCT00993083 ·Status: COMPLETED ·Phase: PHASE2